Navigation Links
Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
Date:4/28/2011

ostridium difficile Recurrence, Alcohol Consumption, and the Effect of Fidaxomicin vs. VancomycinPresenter:

Yoav Golan, M.D., M.S.Date:

Tuesday, May 10, 2011Time:

12:30 p.m. to 1:30 p.m. Central European TimeLocation:

Poster Area Hall 5Poster Topic 99:

Clostridium difficilePoster ID#:

P19682011 Annual Scientific Meeting of the American Geriatrics Society (AGS), The Gaylord National Hotel, National Harbor, MarylandMay 11-14, 2011Poster Presentation Information: Title:

Effect of Advancing Age on Outcomes of Therapy for Clostridium difficile InfectionPresenter:

Thomas J. Louie, M.D.Date:

Thursday, May 12, 2011 Time:

4:30 p.m. to 6:00 p.m. Eastern TimeSession:

Presidential Poster Session BLocation:

Exhibit HallPoster ID#:

B126About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has two anti-infective product candidates in development, DIFICID™ (fidaxomicin) and Pruvel™ (prulifloxacin). DIFICID is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). The FDA granted the Company's request for six-month Priority Review of Optimer's NDA for DIFICID, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. The Company also filed a MAA with the European Medicines Agency (EMA) for DIFICID. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.  

ContactsOptimer Pharmaceuticals, Inc.
Christina Donaghy, Corporate Communications Manager
John D. Prunty, Chief Financial Officer & VP
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
3. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
6. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
7. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
8. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
9. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
10. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
11. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014 SeqLL Inc., the ... technology, announced today the closing of a $1M ... by Genomic Diagnostic Technologies, will increase the power ... , Founded in March 2013 by Daniel Jones, ... at Helicos BioSciences, SeqLL has continued to offer ...
(Date:9/18/2014)... new microscopy technology that allows them to view ... , Dubbed "Complementation Activated Light Microscopy" (CALM), the ... order of magnitude finer than conventional optical microscopy, ... at the nanometer scale. , In a paper ... , the researchers behind CALM used it to ...
(Date:9/18/2014)... 18, 2014 Pipette.com announces brand ... Socorex, Capp, and AccuPet brand of pipettes. Micropipettes ... uL or less and are a great tool ... , The micropipette promotions were designed to ... alternative products to help customers find the right ...
(Date:9/17/2014)... Sept. 17, 2014 A long-term retrospective ... breast irradiation (APBI) via interstitial brachytherapy suggests that ... lymph nodes could be suitable to receive the ... guidelines place these patients in the "unsuitable" category ... 2014 ASTRO meeting, Beaumont Health System,s Peter ...
Breaking Biology Technology:SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2Scientists pioneer microscopy technique that yields fresh data on muscular dystrophy 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4
... ... Inc. 5000 , ... Boston, MA (PRWEB) August 13, 2009 -- Inc. magazine announced on Wednesday its 2009 ... a diversified technology solutions company and a leader in web-database solutions, healthcare intelligence and ...
... National Physical Laboratory (NPL) in Teddington have developed imaging technology ... minimise wastage and solve an impending labour shortage for UK ... to 60% - which can mean up to 100,000 of ... farmers who were consulted during research. Falling number of migrant ...
... , , OMAHA, Neb., Aug. ... the quarter ended June 30, 2009. The Company,s financial results are presented in ... , The Company reported a net loss of $730,000 or $0.01 per ... $101,000 or $0.00 per share for the second quarter of 2008. , ...
Cached Biology Technology:Massachusetts Technology Corporation Named to Inc. 5000 List of Fastest Growing Private Companies 2UK scientists developing intelligent harvesting robot to save farms up to 100,000 a year 2Transgenomic, Inc. Reports Second Quarter 2009 Results 2Transgenomic, Inc. Reports Second Quarter 2009 Results 3Transgenomic, Inc. Reports Second Quarter 2009 Results 4Transgenomic, Inc. Reports Second Quarter 2009 Results 5Transgenomic, Inc. Reports Second Quarter 2009 Results 6Transgenomic, Inc. Reports Second Quarter 2009 Results 7Transgenomic, Inc. Reports Second Quarter 2009 Results 8
(Date:9/18/2014)... 2014 -- Arizona turned its newborn screening program into a ... months, earning it the first-ever Newborn Screening Quality Award from ... presented Will Humble, M.P.H., Arizona,s Department of Health Services director, ... Humble established a policy of full transparency for the length ... samples to the lab for analysis, and set a target ...
(Date:9/18/2014)... rabbitfish which have devastated algal forests in the eastern ... Mediterranean basin if their distribution continues to expand as ... by an international team of researchers led by Dr ... of the Mediterranean Institute for Advanced Studies in Spain, ... Members of the team surveyed more than 1000 kilometres ...
(Date:9/18/2014)... the fish world, are the ideal animal in which ... moved from the ocean into tens of thousands of ... changing their skeleton to adapt to the new environment. ... sticklebacks now have turned up one of the genes ... change in that gene,s regulation in a freshwater population ...
Breaking Biology News(10 mins):March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 3Tropical fish a threat to Mediterranean Sea ecosystems 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3
... collaboration with the Technical University of Braunschweig (TUBS), Germany ... autonomous unmanned aerial vehicles (UAVs) in Antarctica. This is ... in the Antarctic and the successful flights open up ... the harshest and remotest environment on Earth. Dr ...
... study, researchers taking advantage of improvements in satellite sensor ... of pollution from East Asian forest fires, urban exhaust, ... North America. China, the worlds most populated country, ... urban areas, and considerable expansion in automobile use over ...
... Human diseases and social networks would seem to ... of these two lies a network,communities within the ... In a recent paper in Physical Review E ... computer science and engineering and of genetics, and ...
Cached Biology News:Unmanned aerial vehicles mark robotic first for British Antarctic Survey 2NASA satellite measures pollution from east Asia to North America 2NASA satellite measures pollution from east Asia to North America 3Algorithm finds the network -- for genes or the Internet 2Algorithm finds the network -- for genes or the Internet 3
... polyclonal to ErbB 2 - BSA ... for all tested applications). ... conjugated to KLH, corresponding to C ... c-ErbB2 Entrez GeneID: ...
SHP-2 Antibody...
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
Mouse monoclonal [RIZ1723] to PRDM2/RIZ...
Biology Products: